{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Gilead Sciences, Inc.
Gilead Sciences Hits Day High with Strong 3.6% Intraday Surge
Gilead Sciences, Inc. has shown notable market activity, achieving an intraday high and delivering a substantial annual return. The company boasts strong fundamentals, including a high Return on Capital Employed and a low Debt to EBITDA ratio, reflecting its financial stability and efficient management. Institutional confidence is also evident.
Gilead Sciences Experiences Valuation Adjustment Amid Strong Market Performance Indicators
Gilead Sciences, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 16 and a price-to-book value of 7.76. The company demonstrates strong operational performance with high ROCE and ROE figures. Gilead has outperformed the S&P 500 over the past year, reflecting its competitive market position.
Is Gilead Sciences, Inc. overvalued or undervalued?
As of October 17, 2025, Gilead Sciences, Inc. is considered very expensive and overvalued compared to its peers, with a P/E ratio of 15 and stagnant long-term returns, despite a strong year-to-date performance of 32.95%.
Gilead Sciences Experiences Valuation Adjustment Amid Strong Market Performance and Metrics
Gilead Sciences, Inc. has recently adjusted its valuation, with its current price reflecting a significant increase from the previous close. Over the past year, the company has achieved a strong return, outperforming the S&P 500. Key financial metrics indicate Gilead's solid market position and operational efficiency compared to its peers.
Is Gilead Sciences, Inc. overvalued or undervalued?
As of October 17, 2025, Gilead Sciences, Inc. is considered very expensive and overvalued compared to its peers, with a P/E ratio of 15 and a significant underperformance in long-term returns relative to the S&P 500.
Is Gilead Sciences, Inc. overvalued or undervalued?
As of October 17, 2025, Gilead Sciences, Inc. is considered very expensive with overvaluation indicators despite strong performance, as its P/E ratio is lower than the peer average and its PEG ratio suggests premium pricing relative to peers.
Gilead Sciences, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
Gilead Sciences, Inc. has recently revised its evaluation amid changing market conditions. The stock is priced at $112.49, with a notable annual return of 34.01%, surpassing the S&P 500. Technical indicators present a mixed outlook, reflecting both bullish and bearish trends across different timeframes.
Is Gilead Sciences, Inc. technically bullish or bearish?
As of September 19, 2025, Gilead Sciences, Inc. shows a bullish technical trend with mixed signals, having outperformed the S&P 500 year-to-date and over the past year, but underperformed over the last five years.
Is Gilead Sciences, Inc. technically bullish or bearish?
As of September 19, 2025, Gilead Sciences, Inc. is in a bullish trend, supported by positive daily moving averages and KST signals, though short-term indicators like the weekly MACD and OBV show mild bearishness, reflecting mixed signals despite strong year-to-date performance.
Is Gilead Sciences, Inc. technically bullish or bearish?
As of September 5, 2025, Gilead Sciences, Inc. shows a bullish trend overall, despite mixed signals from the MACD and OBV, with a year-to-date return of 23.01% compared to the S&P 500's 12.22%.
Is Gilead Sciences, Inc. overvalued or undervalued?
As of July 7, 2025, Gilead Sciences, Inc. is considered very expensive and overvalued due to its lower P/E ratio compared to peers, despite strong profitability metrics and recent stock performance that has outpaced the S&P 500 year-to-date.
Is Gilead Sciences, Inc. technically bullish or bearish?
As of June 2, 2025, Gilead Sciences, Inc. shows a mildly bullish trend with daily moving averages indicating bullish momentum, but weekly indicators suggest caution due to mildly bearish MACD and KST, while the monthly outlook remains bullish despite a bearish RSI.
Is Gilead Sciences, Inc. overvalued or undervalued?
As of February 13, 2025, Gilead Sciences, Inc. is considered very expensive and overvalued, with a P/E ratio of 15 compared to the industry average of 21.64, an EV to EBITDA ratio of 11.39, and recent stock performance lagging behind the S&P 500.
Who are in the management team of Gilead Sciences, Inc.?
As of March 2022, Gilead Sciences, Inc.'s management team includes Chairman and CEO Daniel O'Day, Lead Independent Director Kevin Lofton, Directors Jeffrey Bluestone, Javier Rodriguez, Anthony Welters, and Independent Director Jacqueline Barton. They are responsible for the company's strategic direction and operations.
What does Gilead Sciences, Inc. do?
Gilead Sciences, Inc. is a large-cap biopharmaceutical company focused on discovering, developing, and commercializing medicines, with a net sales of $6.646 billion and a market cap of approximately $134.34 billion as of March 2025. Key financial metrics include a P/E ratio of 15.00 and a dividend yield of 2.89%.
How big is Gilead Sciences, Inc.?
As of Jun 18, Gilead Sciences, Inc. has a market capitalization of $134.34 billion, with net sales of $28.69 billion and a net profit of $5.97 billion over the latest four quarters. The company's total assets amount to $58.99 billion, with shareholder's funds of $19.33 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
